Vascular endothelial growth factor receptors, fibroblast growth factor receptors, and platelet-derived growth factor receptors (VEGFR/FGFR/PDGFR)

This target profile represents a cluster of receptor tyrosine kinases (RTKs) including Vascular Endothelial Growth Factor Receptors (VEGFR 1-3), Fibroblast Growth Factor Receptors (FGFR 1-4), and Platelet-Derived Growth Factor Receptors (PDGFR alpha/beta). These receptors are primarily expressed on endothelial cells, pericytes, and fibroblasts, where they orchestrate the complex process of angiogenesis and vascular stabilization [NIH, 2023]. VEGFRs are the master regulators of endothelial cell mitogenesis and permeability, while PDGFRs facilitate the recruitment of mural cells to support vessel integrity, and FGFRs act as potent co-regulators and provide escape mechanisms for tumor-induced blood vessel growth [UniProt, 2024]. In pathological states such as malignancy and fibrotic diseases, these pathways are frequently co-opted to drive tumor neovascularization or excessive tissue scarring. Therapeutic agents targeting this triad, known as multi-kinase inhibitors, are designed to provide a comprehensive blockade of the angiogenic switch, reducing the likelihood of resistance compared to agents targeting VEGF alone [PubMed, PMC5720531]. These drugs, such as nintedanib and lenvatinib, are standard of care in various solid tumors and interstitial lung diseases, though their broad activity profile often leads to characteristic systemic toxicities like hypertension and impaired wound healing [FDA, 2023].

Other names

Vascular endothelial growth factor receptorsFibroblast growth factor receptorsPlatelet-derived growth factor receptorsAngiogenesis-related receptor tyrosine kinasesMulti-kinase inhibitor targetsVEGFR1 (FLT1)VEGFR2 (KDR)VEGFR3 (FLT4)FGFR1FGFR2FGFR3FGFR4PDGFRAPDGFRB

Small molecule inhibition of the intracellular tyrosine kinase domains by competing with adenosine triphosphate (ATP) for binding sites, which prevents receptor autophosphorylation and blocks downstream signaling cascades such as the RAS/MAPK and PI3K/AKT pathways essential for endothelial cell survival and proliferation [StatPearls, 2023; Nature Reviews Cancer, 2017].